Skip to content
10-Q

Quarterly Report

RECURSION PHARMACEUTICALS, INC. RXRX

0001601830-25-000166

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2025 · Sep 30, 2025 446.99M sh
Shares Diluted Q3 2025 · Sep 30, 2025 422.64M sh
Shares Diluted Q3 2025 · Sep 30, 2024 282.58M sh
Shares Diluted Q3 2025 · Sep 30, 2024 253.45M sh
Capex Q3 2025 · Sep 30, 2025 $5.23M
Capex Q3 2025 · Sep 30, 2024 $12.4M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$325.74M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$243.74M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $659.84M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $594.35M
Stockholders Equity Q3 2025 · Sep 30, 2025 $1.05B
Stockholders Equity Q3 2025 · Jun 30, 2025 $919.15M
Stockholders Equity Q3 2025 · Dec 31, 2024 $1.03B
Stockholders Equity Q3 2025 · Sep 30, 2024 $524.56M
Stockholders Equity Q3 2025 · Jun 30, 2024 $584.45M
Stockholders Equity Q3 2025 · Dec 31, 2023 $463.44M
Current Liabilities Q3 2025 · Sep 30, 2025 $155.1M
Current Liabilities Q3 2025 · Dec 31, 2024 $187.47M
Total Liabilities Q3 2025 · Sep 30, 2025 $352.58M
Total Liabilities Q3 2025 · Dec 31, 2024 $413.82M
Current Assets Q3 2025 · Sep 30, 2025 $714.11M
Current Assets Q3 2025 · Dec 31, 2024 $714.27M
Total Assets Q3 2025 · Sep 30, 2025 $1.4B
Total Assets Q3 2025 · Dec 31, 2024 $1.45B
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.36
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.27
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.34
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.12
Eps Basic Q3 2025 · Sep 30, 2025 −$0.36
Eps Basic Q3 2025 · Sep 30, 2025 −$1.27
Eps Basic Q3 2025 · Sep 30, 2024 −$0.34
Eps Basic Q3 2025 · Sep 30, 2024 −$1.12
Sga Expense Q3 2025 · Sep 30, 2025 $41.63M
Sga Expense Q3 2025 · Sep 30, 2025 $142.93M
Sga Expense Q3 2025 · Sep 30, 2024 $37.76M
Sga Expense Q3 2025 · Sep 30, 2024 $101M
Rd Expense Q3 2025 · Sep 30, 2025 $121.06M
Rd Expense Q3 2025 · Sep 30, 2025 $379.33M
Rd Expense Q3 2025 · Sep 30, 2024 $74.6M
Rd Expense Q3 2025 · Sep 30, 2024 $216.09M
Net Income Q3 2025 · Sep 30, 2025 −$162.25M
Net Income Q3 2025 · Sep 30, 2025 −$536.64M
Net Income Q3 2025 · Sep 30, 2024 −$95.84M
Net Income Q3 2025 · Sep 30, 2024 −$284.76M
Operating Income Q3 2025 · Sep 30, 2025 −$172.2M
Operating Income Q3 2025 · Sep 30, 2025 −$539.8M
Operating Income Q3 2025 · Sep 30, 2024 −$98.35M
Operating Income Q3 2025 · Sep 30, 2024 −$295.24M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $14.69M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $56.68M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $12.08M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $32.44M
Revenue Q3 2025 · Sep 30, 2025 $5.18M
Revenue Q3 2025 · Sep 30, 2025 $39.14M
Revenue Q3 2025 · Sep 30, 2024 $26.08M
Revenue Q3 2025 · Sep 30, 2024 $54.29M